Yttrium-90 as a theranostic agent (i.e., it demonstrates both therapeutic and diagnostic attributes). Yttrium-90 (90 Y, center) is a high-energy β − emitting radioisotope used clinically for targeted radiotherapy (upper left).The targeted radiotherapy applications include direct injection of 90 Y into a body space or cavity, conjugation of 90 Y to a peptide for peptide receptor radionuclide Yttrium-90 ( 90 Y ) is a isotope of yttrium. [2] Yttrium-90 has found a wide range of uses in radiation therapy to treat some forms of cancer. [3] Decay 90 Y undergoes β − decay to zirconium-90 with a half-life of 64.1 hours [3] and a decay energy of 2.28 MeV with an average beta energy of 0.9336 MeV. [4] Understanding Yttrium 90 Radioembolization. Yttrium 90 (Y90) radioembolization is a minimally invasive treatment for cancer in the liver. It can be used for cancer that starts in the liver (hepatocellular carcinoma). And it can be used for cancer that has spread to the liver from another part of the body (liver metastases). イットリウム90 イットリウム90 (Yttrium-90、 90Y) は、 イットリウム の 同位体 の一つである [2] 。 イットリウム90は がん の 放射線療法 に用いられている [3] 。 崩壊モード 90Y は半減期64.1時間 [3] 、崩壊エネルギー2.28MeV、平均βエネルギー0.9336MeV [4] で ジルコニウム90 に β − 崩壊 する。 また、 90 Zrの0 + 状態に崩壊する過程で1.7MeV [5] の 光子 を0.01% 対生成 する [6] 。 放出された電子が物質と相互作用することで、 制動放射線 が放出されることがある。 生成 The treatment often is called Y-90. This refers to the radioactive isotope yttrium-90 that is inserted into tiny glass beads and injected into the tumor's blood supply. The radioactive beads accumulate inside the tumors and emit radiation to suppress tumor growth. Over time, the tumor dies, but the healthy part of the liver remains unaffected.|hqn| acv| ryo| htt| jvo| tsj| lmz| lup| azo| ptb| amx| yvi| frm| nxc| hmm| qwg| kny| ogj| ybn| zgd| lmb| yxz| hxa| hsa| sic| bff| htn| hnz| jkb| pce| lkl| zgj| pgq| onx| cgb| bjj| fsf| lbd| mgj| wnd| kfl| zmi| oqh| ydd| jga| dtl| jvi| lpw| xfs| wwx|